International Journal of Hematology

, Volume 84, Issue 2, pp 182–185 | Cite as

Successful Treatment of a Patient with POEMS Syndrome by Tandem High-Dose Chemotherapy with Autologous CD34+ Purged Stem Cell Rescue

  • Hiroshi Kojima
  • Yuna Katsuoka
  • Yukitaka Katsura
  • Sachie Suzuki
  • Kazumi Suzukawa
  • Yuichi Hasegawa
  • Toshiro Nagasawa
Case Report


A 36-year-old man was admitted because of numbness and muscle weakness in the lower extremities. He had gait disturbance, malaise, and body weight loss. Based on the existence of monoclonal gammopathy, the proliferation of abnormal plasma cells in the bone marrow, the presence of sclerotic bone lesion, polycythemia, mild splenomegaly, and an elevated level of serum vascular endothelial growth factor (VEGF) (14,900 pg/mL; normal, 62-707), he was diagnosed as having peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Following 2 courses of conventional chemotherapy with doxorubicin and dexamethasone, peripheral blood stem cells were mobilized by high-dose etoposide (500 mg/m2 X 3 days) and granulocyte colony-stimulating factor. After purging by CD34+ selection using the CliniMACS device, the selected cells (12.4 X 106/kg) were cryopreserved. He was then treated with tandem high-dose chemotherapy (HDC) (melphalan 100 mg/m2 X 2 days) with autologous stem cell rescue. After the first course of HDC, the serum level of VEGF normalized and the minimal residual disease in the bone marrow was reduced below the detection limit of CDR3 analysis by polymerase chain reaction. The patient has been in remission for more than 20 months. He has gradually recovered from the neurological symptoms and now has no impairments of daily living. Our experience suggests that autologous purged stem cell transplantation should be considered as the treatment of choice for POEMS syndrome.

Key words

POEMS syndrome Tandem high-dose chemotherapy CD34+ purged stem cell rescue 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984;34:712–720.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496–2506.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390–1397.CrossRefGoogle Scholar
  4. 4.
    Hashiguchi T,Arimura K, Matsumuro K, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve. 2000;23:1051–1056.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911–1920.CrossRefPubMedGoogle Scholar
  6. 6.
    Soubrier M, Dubost JJ, Serre AF, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40:786–787.CrossRefPubMedGoogle Scholar
  7. 7.
    Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66:105–107.CrossRefPubMedGoogle Scholar
  8. 8.
    Soubrier M, Ruivard M, Dubost JJ, Sauvezie B, Philippe P. Successful use of autologous bone marrow transplantation in treating a patient with POEMS syndrome. Bone Marrow Transplant. 2002;30:61–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Peggs KS, Paneesha S, Kottaridis PD, et al. Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplant. 2002;30:401–404.CrossRefPubMedGoogle Scholar
  10. 10.
    Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood. 2002;99:3057–3059.CrossRefPubMedGoogle Scholar
  11. 11.
    Rovira M, Carreras E, Blade J, et al. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. Br J Haematol. 2001;115:373–375.CrossRefPubMedGoogle Scholar
  12. 12.
    Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502.CrossRefGoogle Scholar
  13. 13.
    Trainor KJ, Brisco MJ, WanGene JH, et al. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood. 1991;78:192–196.PubMedGoogle Scholar
  14. 14.
    Imai Y, Chou T, Tobinai K, et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin’s lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant. 2005;35:479–487.CrossRefPubMedGoogle Scholar
  15. 15.
    Damiani D, Stocchi R, Masolini P, et al. CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. Ann Oncol. 2003;14:475–480.CrossRefPubMedGoogle Scholar
  16. 16.
    Frere P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006;76:102–108.CrossRefPubMedGoogle Scholar
  17. 17.
    Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–3779.CrossRefPubMedGoogle Scholar
  18. 18.
    Galimberti S, Morabito F, Guerrini F, et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol. 2003;120:405–412.CrossRefPubMedGoogle Scholar
  19. 19.
    Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214–218.CrossRefPubMedGoogle Scholar
  20. 20.
    Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95:2234–2239.PubMedGoogle Scholar
  21. 21.
    Vital C,Vital A, Ferrer X, et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst. 2003;8:136–144.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Hiroshi Kojima
    • 1
  • Yuna Katsuoka
    • 1
  • Yukitaka Katsura
    • 1
  • Sachie Suzuki
    • 1
  • Kazumi Suzukawa
    • 1
  • Yuichi Hasegawa
    • 1
  • Toshiro Nagasawa
    • 1
  1. 1.Division of Hematology, Institute of Clinical MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations